Rubidium Chloride

Summary

Rubidium Chloride (CHEMBL2110557) is an approved small-molecule antidepressant.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 120.92 Da · ClRb

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110557
Name	Rubidium Chloride
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	62683
ChEBI	CHEBI:78672
Molecular formula	ClRb
Molecular weight	120.92
InChIKey	FGDZQCVHDSGLHJ-UHFFFAOYSA-M

SMILES: [Cl-].[Rb+]

IUPAC name: rubidium(1+) chloride

ChEBI definition: An inorganic chloride composed of rubidium and chloride ions in a 1:1 ratio.

Pharmacological roles (ChEBI): antidepressant, biomarker.

Other ChEBI roles (chemical / environmental): NMR chemical shift reference compound.

Parent form; salt/anhydrous children: CHEMBL1200727

Patent coverage: 5,225 distinct patent families (13,563 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 10,181 (75%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).